Supplementation of very low birthweight (VLBW) babies with probiotic Bifidobacterium breve strain (BBG): a pilot study of tolerability and feasibility

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN99401619

Enrollment

Registered

2003-09-12

Start date

2002-01-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal Diseases: Low birth weight Neonatal Diseases Low birth weight

Interventions

Randomised controlled trial, 20 per group to be fed live or killed BBG. Group A: Bifidobacterium breve live strain Group B: Placebo (BBG killed strain)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Preterm babies more than 500 but less than 1500 g birthweight with no life threatening congenital malformations

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Thus is a pilot study of tolerability and feasibility. The main study will investigate whether BBG supplement is associated with reduced infection and antibiotic usage in this population.	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026